Trade JnJ ^JNJ

Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock - AOL

Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story

Johnson & Johnson (JNJ) Jury Rules in Favor of Company in Talc Lawsuit

Vestcor Inc Boosts Stock Position in Johnson & Johnson $JNJ

102,246 Shares in Johnson & Johnson $JNJ Bought by PBU The Pension Fund of Early Childhood & Youth Educators - Zolmax

111 Capital Makes New $1.74 Million Investment in Johnson & Johnson $JNJ

Arsenal Capital Advisors LLC Takes Position in Johnson & Johnson $JNJ

111 Capital Purchases Shares of 8,416 Johnson & Johnson $JNJ - Stock Observer

Johnson & Johnson beats lawsuit alleging that talc caused 3 women's cancer | The Straits Times

PBU The Pension Fund of Early Childhood & Youth Educators Buys New Position in Johnson & Johnson $JNJ - Daily Political

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson (NYSE:JNJ) Stock Price Up 2% - Still a Buy? - Zolmax

Johnson & Johnson (NYSE:JNJ) Shares Up 2% - Still a Buy?

Erste Group downgrades Deutsche Telekom (0MPH) to a Hold

Johnson & Johnson (JNJ) Gets a Buy from Guggenheim

Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations

Is It Time To Reassess Johnson & Johnson (JNJ) After A 52% One-Year Surge? - Simply Wall St News

Johnson & Johnson $JNJ Shares Sold by J.W. Cole Advisors Inc. - Zolmax

Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target

Total Wealth Planning & Management Inc. Takes $1.03 Million Position in Johnson & Johnson $JNJ - Zolmax

4,997 Shares in Johnson & Johnson $JNJ Bought by Total Wealth Planning & Management Inc.

313,929 Shares in Johnson & Johnson $JNJ Acquired by Arrowpoint Investment Partners Singapore Pte. Ltd.

Daiwa Securities Group Inc. Grows Position in Johnson & Johnson $JNJ - Stock Observer

Prudential PLC Has $81.29 Million Stock Holdings in Johnson & Johnson $JNJ - Daily Political

Johnson & Johnson $JNJ Shares Purchased by Deseret Mutual Benefit Administrators - Stock Observer

Vise Technologies Inc. Has $20.93 Million Stock Holdings in Johnson & Johnson $JNJ - Daily Political

Prestige Wealth Management Group LLC Has $7.04 Million Position in Johnson & Johnson $JNJ - Daily Political

Johnson & Johnson (NYSE:JNJ) Trading 2.3% Higher - Time to Buy?

JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns

Jim Cramer's 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities

Top Healthcare Stocks To Add to Your Watchlist - June 4th - Zolmax

This Dividend King Is the Safest Dow Stock to Buy and Hold for 20 Years

Johnson And Johnson Autoimmune Trial Data And What It Means For JNJ

TD Asset Management Inc Increases Stock Holdings in Johnson & Johnson $JNJ

WCG Wealth Advisors LLC Acquires 22,434 Shares of Johnson & Johnson $JNJ

Greenspring Advisors LLC Purchases Shares of 7,353 Johnson & Johnson $JNJ

Johnson & Johnson $JNJ Position Boosted by Cibc World Market Inc.

Platform Wealth Management LLC Takes Position in Johnson & Johnson $JNJ - Stock Observer

Greenspring Advisors LLC Makes New Investment in Johnson & Johnson $JNJ - Stock Observer

First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment | Hindustan Times

Cibc World Market Inc. Acquires 70,817 Shares of Johnson & Johnson $JNJ - Stock Observer

Paul Hastings Settles With J&J Unit in Bankruptcy Fee Dispute

Mawer Investment Management Ltd. Acquires 14,220 Shares of Johnson & Johnson $JNJ - Zolmax

Johnson & Johnson (JNJ) Reports Positive Results for Lupus Treatment Nipocalimab

Johnson & Johnson (JNJ) Reveals Promising Data for Sjogren's Disease Treatment

Kesler Norman & Wride LLC Sells 38,128 Shares of Johnson & Johnson $JNJ

One Capital Management LLC Sells 33,786 Shares of Johnson & Johnson $JNJ

First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment

Johnson & Johnson (JNJ) Stock Rises on Positive Nipocalimab Lupus Trial Data

Johnson & Johnson $JNJ Shares Purchased by CIBC Asset Management Inc

Bank of New York Mellon Corp Cuts Stake in Johnson & Johnson $JNJ

Johnson & Johnson (JNJ) Reports Positive Phase 2 Results for Lupus Treatment

JNJ's Nipocalimab Meets Primary Goal In Phase 2 JASMINE Trial Of Systemic Lupus Erythematosus

Johnson & Johnson $JNJ Shares Sold by Westpac Banking Corp - Daily Political

A Look At Johnson & Johnson (JNJ) Valuation After Recent Share Price Weakness - Simply Wall St News

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study | Morningstar

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease | Morningstar

Top Healthcare Stocks To Watch Now - June 2nd - Daily Political

Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic - AOL

Vantus Wealth LLC Makes New $995,000 Investment in Johnson & Johnson $JNJ

Natixis Advisors LLC Grows Stake in Johnson & Johnson $JNJ

Pincus Capital Management LP Invests $1.60 Million in Johnson & Johnson $JNJ

Johnson & Johnson $JNJ Position Raised by BNP Paribas

Citrate-functionalized manganese oxide nanoparticles in neonates ≥35 weeks gestation at risk of acute bilirubin encephalopathy: a phase 1 observational trial

Medical Stocks To Follow Today - June 1st - Stock Observer

JNJ DCF Analysis: Intrinsic Value $122 vs Price $225

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

Easterly Investment Partners LLC Lowers Holdings in Johnson & Johnson $JNJ

Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?

Sage Investment Advisers LLC Purchases New Stake in Johnson & Johnson $JNJ - Daily Political

Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?

Johnson & Johnson (JNJ) Reports Positive Phase 3 Study Results for Prostate Cancer Treatment

J&J's Erleada: Game-Changer in Prostate Cancer Treatment, ETPharma

How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

Johnson & Johnson (JNJ) Reports Promising Trial Results for Amivantamab in Cancer Treatment

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivot

J&J therapy shows strong survival benefit in prostate cancer patients

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm | Morningstar

Johnson & Johnson $JNJ Shares Sold by Mitchell Capital Management Co. - Zolmax

Johnson & ​Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study - The Economic Times

Top Healthcare Stocks To Consider - May 31st - Daily Political

Welch & Forbes LLC Lowers Holdings in Johnson & Johnson $JNJ

Essex Financial Services Inc. Buys 2,492 Shares of Johnson & Johnson $JNJ - Stock Observer

Nomura Asset Management Co. Ltd. Has $299.45 Million Stake in Johnson & Johnson $JNJ - Daily Political

Founders Financial Securities LLC Increases Stock Holdings in Johnson & Johnson $JNJ - Daily Political

Top Medical Stocks To Follow Today - May 30th - Stock Observer

How to Recession-Proof Your Retirement Income Before Summer 2026

 Week Ahead: Inflation Data from U.S., Canada, and U.K. Take Centre Stage

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Week Ahead: BoC and ECB Interest Rate Decisions in Focus This Week

Week ahead: ECB set to cut as Wall Street earnings season gathers pace

Week ahead: US earnings season kicks off, ECB hold expected

Europe Tries to Ride on US Coat-tails

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk